XCancer

SPECT/CT for the Characterization of Renal Masses

Description:

This trial studies how well technetium Tc-99m sestamibi single-photon emission computed tomography/computed tomography (SPECT/CT) works on clinical decision making in patients with kidney tumors. Diagnostic procedures, such as technetium Tc-99m sestamibi SPECT/CT may be a less invasive way to check for kidney tumors.

Sponsor:

Jonsson Comprehensive Cancer Center (UCLA)

Contacts:

Brian Shuch (PRINCIPAL_INVESTIGATOR)

Government Study Link:

NCT03996850 - Click here to see study on

ClinicalTrials.gov

sestamibi

Isotope(s):
Target(s):
  • Mitochondria-Targeting Moieties
Ligand Class: Small Molecules
Inclusion
  • New diagnosis of a renal tumor (within past 3 months).
  • Measurable, predominantly (\> 80%) solid renal neoplasm between 1.5-5.0 cm.
  • Life expectancy (\> 1 year).
  • * Performance status Eastern Cooperative Oncology Group (ECOG) \< 2.
  • Lesion concerning for kidney cancer bases on a contrast-enhanced CT or magnetic resonance imaging (MRI).
Exclusion
  • Presence of an active, untreated, non-renal malignancy.
  • History of bleeding diathesis or recent bleeding episode.
  • A prior needle biopsy of the mass resulting in histologic diagnosis.
  • * Presence of multiple solid renal tumors.
  • A prior diagnosis of kidney cancer.

Patient Education

Patient Education Not Yet Provided

Publications

Publications Not Yet Provided

Locations

Loading...